

# Daniela Dornelles Rosa

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5361246/publications.pdf>

Version: 2024-02-01

34  
papers

952  
citations

471509

17  
h-index

454955

30  
g-index

35  
all docs

35  
docs citations

35  
times ranked

1947  
citing authors

#	ARTICLE	IF	CITATIONS
1	Chemobrain in Breast Cancer: Mechanisms, Clinical Manifestations, and Potential Interventions. <i>Drug Safety</i> , 2022, 45, 601-621.	3.2	10
2	What Cancer Patients Want to Know? Questions from Oncologic Patients in a Brazilian Private Cancer Center. <i>Journal of Cancer Education</i> , 2021, 36, 106-109.	1.3	0
3	Impact of the COVID-19 Pandemic on Oncology Clinical Research in Latin America (LACOG 0420). <i>JCO Global Oncology</i> , 2021, 7, 649-658.	1.8	19
4	Managing Common Estrogen Deprivation Side Effects in HR+ Breast Cancer: an Evidence-Based Review. <i>Current Oncology Reports</i> , 2021, 23, 63.	4.0	3
5	Brain imaging and treatment modality of central nervous system metastasis: A single institution cohort. <i>Breast Journal</i> , 2020, 26, 812-814.	1.0	0
6	The impact of sociodemographic factors and health insurance coverage in the diagnosis and clinicopathological characteristics of breast cancer in Brazil: AMAZONA III study (GBECAM 0115). <i>Breast Cancer Research and Treatment</i> , 2020, 183, 749-757.	2.5	31
7	Breast cancer survival in Brazil: How much health care access impact on cancer outcomes?. <i>Breast</i> , 2020, 54, 155-159.	2.2	9
8	Biological features of breast cancer according to age at diagnosis in southern Brazil: An analysis of retrospective data of 1128 women. <i>Breast Journal</i> , 2019, 25, 760-762.	1.0	4
9	Characteristics and prognosis of stage I-III breast cancer subtypes in Brazil: The AMAZONA retrospective cohort study. <i>Breast</i> , 2019, 44, 113-119.	2.2	68
10	Effects of physical exercise after treatment of early breast cancer: systematic review and meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2018, 170, 455-476.	2.5	40
11	Adjuvant Dose-Dense Chemotherapy for Breast Cancer: Available Evidence and Recent Updates. <i>Breast Care</i> , 2018, 13, 447-452.	1.4	9
12	Influence of CYP2D6 and CYP3A4 Phenotypes, Drug Interactions, and Vitamin D Status on Tamoxifen Biotransformation. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 733-744.	2.0	21
13	CYP3A4*22 is related to increased plasma levels of 4-hydroxytamoxifen and partially compensates for reduced CYP2D6 activation of tamoxifen. <i>Pharmacogenomics</i> , 2015, 16, 601-617.	1.3	24
14	Development, validation and clinical application of a HPLC-FL method for CYP2D6 phenotyping in South Brazilian breast cancer patients. <i>Clinical Biochemistry</i> , 2014, 47, 1084-1090.	1.9	7
15	Incidence of Cancer Following Bariatric Surgery: Systematic Review and Meta-analysis. <i>Obesity Surgery</i> , 2014, 24, 1499-1509.	2.1	79
16	Sensitive HPLC-PDA determination of tamoxifen and its metabolites N-desmethyltamoxifen, 4-hydroxytamoxifen and endoxifen in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2013, 76, 13-20.	2.8	37
17	Endoxifen Levels and Its Association With CYP2D6 Genotype and Phenotype. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 422-431.	2.0	31
18	Accuracy of telomerase in estimating breast cancer risk: A systematic review and meta-analysis. <i>Breast</i> , 2012, 21, 1-7.	2.2	7

#	ARTICLE	IF	CITATIONS
19	Accuracy of magnetic resonance in suspicious breast lesions: a systematic quantitative review and meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2011, 126, 273-285.	2.5	69
20	Pharmacokinetic evaluation of doxorubicin plasma levels in normal and overweight patients with breast cancer and simulation of dose adjustment by different indexes of body mass. <i>European Journal of Pharmaceutical Sciences</i> , 2010, 41, 458-463.	4.0	117
21	Oxaliplatin/5fluorouracil-based chemotherapy was active and well tolerated in heavily pretreated patients with ovarian carcinoma. <i>Archives of Gynecology and Obstetrics</i> , 2008, 278, 457-462.	1.7	14
22	Molecular-targeted therapies: Lessons from years of clinical development. <i>Cancer Treatment Reviews</i> , 2008, 34, 61-80.	7.7	45
23	Novel cytotoxic drugs: Old challenges, new solutions. <i>Cancer Treatment Reviews</i> , 2008, 34, 81-91.	7.7	83
24	Chronic mucocutaneous candidiasis and oesophageal cancer. <i>Medical Mycology</i> , 2008, 46, 85-91.	0.7	50
25	Antiangiogenic therapy for ovarian cancer. <i>Current Opinion in Oncology</i> , 2007, 19, 497-505.	2.4	12
26	The 17q12-q21 amplicon: Her2 and topoisomerase-III± and their importance to the biology of solid tumours. <i>Cancer Treatment Reviews</i> , 2007, 33, 64-77.	7.7	69
27	Textbook of Uncommon Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 1259.	7.4	2
28	Trastuzumab (Herceptin) for Early-Stage Breast Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2007, 21, 239-256.	2.2	6
29	Heparanase gene haplotype (CGC) is associated with stage of disease in patients with ovarian carcinoma. <i>Cancer Science</i> , 2007, 98, 844-849.	3.9	19
30	The Best Guess Approach to Phase I Trial Design. <i>Journal of Clinical Oncology</i> , 2006, 24, 206-208.	1.6	16
31	OPTIMOX1 in Advanced Colorectal Cancer: Lack of Evidence for a Stop-and-Go Strategy. <i>Journal of Clinical Oncology</i> , 2006, 24, 5176-5177.	1.6	4
32	Technology evaluation: VEGF Trap (cancer), Regeneron/sanofi-aventis. <i>Current Opinion in Molecular Therapeutics</i> , 2005, 7, 493-501.	2.8	10
33	Deficiency of the eighth component of complement associated with recurrent meningococcal meningitis: case report and literature review. <i>Brazilian Journal of Infectious Diseases</i> , 2004, 8, 328-330.	0.6	8
34	Retrospective study of 668 cultures for mycobacteria in a reference hospital for AIDS in Southern Brazil. <i>Brazilian Journal of Infectious Diseases</i> , 2003, 7, 126-8.	0.6	5